Search

Your search keyword '"Avihingsanon A"' showing total 93 results
Start Over Author "Avihingsanon A" Publisher lippincott williams & wilkins
93 results on '"Avihingsanon A"'

8. Prevalence and risk of residual viremia after ART in low- and middle-income countries

Author

Gatechompol, Sivaporn, Zheng, Lu, Bao, Yajing, Avihingsanon, Anchalee, Kerr, Stephen J., Kumarasamy, Nagalingeswaran, Hakim, James G., Maldarelli, Frank, Gorelick, Robert J., Welker, Jorden L., Lifson, Jeffrey D., Hosseinipour, Mina C., Eron, Joseph J., and Ruxrungtham, Kiat

Subjects
Adult, Male, HIV molecular and monitoring core gag single copy assay, prevalence, virus diseases, Observational Study, lowand middle-income countries, HIV Infections, residual viremia, Cross-Sectional Studies, Logistic Models, Anti-Retroviral Agents, HIV-1, risk factors, Humans, Female, Viremia, Developing Countries, Research Article, Retrospective Studies
Abstract

In order to design effective strategies to eradicate the HIV, an understanding of persistent viral reservoirs is needed. Many studies have demonstrated HIV residual viremia prevalence in high income countries, data from low- and middle-income countries (LMIC) are limited. We assessed the prevalence, and factors associated with residual viremia in people with HIV (PWH), who were virally-suppressed on antiretroviral therapy (ART) in LMIC. We also compared residual viremia prevalence between the LMIC and US. This is a cross-sectional, retrospective study that utilized stored specimen samples from the AIDS clinical trials group (ACTG) studies A5175 and A5208. The last available sample among participants with plasma HIV RNA

Published
2021

9. CD4/CD8 Ratio Recovery Among People Living With HIV Starting With First-Line Integrase Strand Transfer Inhibitors: A Prospective Regional Cohort Analysis.

Author

Han, Win Min, Avihingsanon, Anchalee, Rajasuriar, Reena, Tanuma, Junko, Mundhe, Sanjay, Lee, Man-Po, Choi, Jun Yong, Pujari, Sanjay, Chan, Yu-Jiun, Somia, Agus, Zhang, Fujie, Kumarasamy, Nagalingeswaran, Tek NG, Oon, Gani, Yasmin, Chaiwarith, Romanee, Pham, Thach Ngoc, Do, Cuong Duy, Ditangco, Rossana, Kiertiburanakul, Sasisopin, and Khol, Vohith

Abstract

Supplemental Digital Content is Available in the Text. Background: We evaluated trends in CD4/CD8 ratio among people living with HIV (PLWH) starting antiretroviral therapy (ART) with first-line integrase strand transfer inhibitors (INSTI) compared with non-INSTI-based ART, and the incidence of CD4/CD8 ratio normalization. Methods: All PLWH enrolled in adult HIV cohorts of IeDEA Asia-Pacific who started with triple-ART with at least 1 CD4, CD8 (3-month window), and HIV-1 RNA measurement post-ART were included. CD4/CD8 ratio normalization was defined as a ratio ≥1. Longitudinal changes in CD4/CD8 ratio were analyzed by linear mixed model, the incidence of the normalization by Cox regression, and the differences in ratio recovery by group-based trajectory modeling. Results: A total of 5529 PLWH were included; 80% male, median age 35 years (interquartile range [IQR], 29–43). First-line regimens were comprised of 65% NNRTI, 19% PI, and 16% INSTI. The baseline CD4/CD8 ratio was 0.19 (IQR, 0.09–0.33). PLWH starting with NNRTI- (P = 0.005) or PI-based ART (P = 0.030) had lower CD4/CD8 recovery over 5 years compared with INSTI. During 24,304 person-years of follow-up, 32% had CD4/CD8 ratio normalization. After adjusting for age, sex, baseline CD4, HIV-1 RNA, HCV, and year of ART initiation, PLWH started with INSTI had higher odds of achieving CD4/CD8 ratio normalization than NNRTI- (P < 0.001) or PI-based ART (P = 0.015). In group-based trajectory modeling analysis, INSTI was associated with greater odds of being in the higher ratio trajectory. Conclusions: INSTI use was associated with higher rates of CD4/CD8 ratio recovery and normalization in our cohort. These results emphasize the relative benefits of INSTI-based ART for immune restoration. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

16. Incident Liver Cirrhosis, Associated Factors, and Cardiovascular Disease Risks Among People Living With HIV: A Longitudinal Study.

Author

Win Min Han, Ueaphongsukkit, Thornthun, Chattranukulchai, Pairoj, Siwamogsatham, Sarawut, Chaiteerakij, Roongruedee, Sophonphan, Jiratchaya, Gatechompol, Sivaporn, Ubolyam, Sasiwimol, Phonphithak, Supalak, Ruxrungtham, Kiat, Tangkijvanich, Pisit, Avihingsanon, Yingyos, Kerr, Stephen J., and Avihingsanon, Anchalee

Published
2021
Full Text
View/download PDF

21. Long-Term TDF-Inclusive ART and Progressive Rates of HBsAg Loss in HIV-HBV Coinfection--Lessons for Functional HBV Cure?

Author

Audsley, Jennifer, Avihingsanon, Anchalee, Littlejohn, Margaret, Bowden, Scott, Matthews, Gail V., Fairley, Christopher K., Lewin, Sharon R., and Sasadeusz, Joe

Abstract

Background: Tenofovir disoproxil fumarate (TDF) is effective in suppressing HIV and hepatitis B virus (HBV) replication in HIV-HBV coinfection although HBV DNA can persist in some individuals on TDF-containing antiretroviral therapy (ART). We initiated a prospective longitudinal study to determine durability of HBV virological control and clinical outcomes after prolonged TDF-based ART in HIV-HBV coinfection. Methods: Ninety-two HIV-HBV coinfected participants on, or about to commence, TDF-containing ART from Australia (n = 41) and Thailand (n = 52) were enrolled. Participants were followed 6-monthly for 2 years, then annually to 5 years. Laboratory and clinical assessments and a serum sample were collected at each study visit. These analyses compare follow-up at 2 and 5 years. Results: 12.0% (95% confidence interval 6.8 to 20.2) of total study entry cohort (n = 92) or 15.3% (95% confidence interval: 8.8 to 25.3) of those with data to year 5 (n = 72) lost hepatitis B surface antigen (HBsAg). The only statistically significant association with HBsAg loss was lower study entry quantitative HBsAg. CD4 T-cell count increased by a median 245 cells/mm3 between the preTDF sample and 5 years of follow-up. By year 5, 98.5% of the cohort had undetectable HBV DNA (<15 IU/mL) and 91.4% had undetectable HIV RNA (<20 copies/mL). Conclusions: HBsAg loss was high and ongoing over 5 years of follow-up in HIV-HBV coinfected individuals on TDF-containing ART and undetectable HBV was almost universal. Although the pattern of HBsAg loss temporarily parallels immune reconstitution, we could not identify predictive immune markers. The high rate of HBsAg loss in HIV-HBV coinfection may offer valuable insights into the search for a functional HBV cure. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

24. Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial.

Author

Kityo, Cissy, Hagins, Debbie, Koenig, Ellen, Avihingsanon, Anchalee, Chetchotisakd, Ploenchan, Supparatpinyo, Khuanchai, Gankina, Natalya, Pokrovsky, Vadim, Voronin, Evgeny, Stephens, Jeffrey L., DeJesus, Edwin, Hui Wang, Acosta, Rima K., Huyen Cao, Quirk, Erin, Martin, Hal, and Makadzange, Tariro

Published
2019
Full Text
View/download PDF

25. Effect of Macrolide Prophylactic Therapy on AIDS-Defining Conditions and HIV-Associated Mortality.

Author

Pasayan, Mark Kristoffer U., S. Mationg, Mary Lorraine, Boettiger, David, Lam, Wilson, Zhang, Fujie, Ku, Stephane Wen-Wei, Merati, Tuti Parwati, Chaiwarith, Romanee, Cuong, Do Duy, Yunihastuti, Evy, Kiertiburanakul, Sasisopin, Van Kinh, Nguyen, Avihingsanon, Anchalee, Sun, Ly Penh, Kamarulzaman, Adeeba, Kantipong, Pacharee, Kumarasamy, Nagalingeswaran, Pujari, Sanjay, Heng Sim, Benedict Lim, and Ng, Oon Tek

Published
2019
Full Text
View/download PDF

26. Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity

Author

Audsley, J, Bent, SJ, Littlejohn, M, Avihingsanon, A, Matthews, G, Bowden, S, Bayliss, J, Luciani, F, Yuen, L, Fairley, CK, Locarnini, S, Lewin, SR, Sasadeusz, J, Audsley, J, Bent, SJ, Littlejohn, M, Avihingsanon, A, Matthews, G, Bowden, S, Bayliss, J, Luciani, F, Yuen, L, Fairley, CK, Locarnini, S, Lewin, SR, and Sasadeusz, J

Abstract

OBJECTIVE: Hepatitis B virus (HBV) can persist in some HIV-HBV coinfected individuals on tenofovir disoproxil fumarate (TDF)-containing combination antiretroviral therapy (cART) but HBV resistance to TDF has not been reported and the source of persistent HBV DNA on TDF is poorly understood. The aims of this study were to assess long-term HBV suppression in HIV-HBV coinfected individuals receiving TDF and investigate quasispecies variation using ultradeep pyrosequencing (UDPS). METHODS: Ninety-two HIV-HBV coinfected participants on, or about to commence, TDF-containing cART were enrolled [Australia (n = 40), Thailand (n = 52)] and followed for 2 years with study visits every 6 months. HBV reverse transcriptase sequencing was performed on samples with HBV DNA more than 400 IU/ml by population-based methods and UDPS. Quasispecies diversity was assessed using Shannon entropy. RESULTS: Over 24 months, viremia was detected at least once in 17% (n = 16) of the cohort. Novel mutations were not identified in on TDF samples tested by population-based sequencing (n = 19). Using UDPS, the median Shannon entropy value in samples prior to TDF in patients aviremic on TDF was not statistically different from those who were viremic on TDF (n = 50; 8.4 and 9.1, respectively, P = 0.9). Longitudinal Shannon entropy analysis of on TDF samples from five participants showed three individuals with significant changes in viral diversity over time. CONCLUSION: Persistent viremia on TDF-containing cART is common but TDF-resistance was not detected. In some individuals, changes in viral diversity over time were observed on TDF which could potentially be active viral replication. Further follow-up will be needed to determine the clinical significance of detectable HBV DNA on TDF-containing cART.

Published
2016

29. No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4+ T-cell counts.

Author

Wright, Edwina J., Grund, Birgit, Robertson, Kevin R., Cysique, Lucette, Brew, Bruce J., Collins, Gary L., Poehlman-Roediger, Mollie, Vjecha, Michael J., Penalva de Oliveira, Augusto César, Standridge, Barbara, Carey, Cate, Avihingsanon, Anchalee, Florence, Eric, Lundgren, Jens D., Arenas-Pinto, Alejandro, Mueller, Nicolas J., Winston, Alan, Nsubuga, Moses S., Lal, Luxshimi, and Price, Richard W.

Published
2018
Full Text
View/download PDF

33. Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity.

Author

Audsley, Jennifer, Bent, Stephen J., Littlejohn, Margaret, Avihingsanon, Anchalee, Matthews, Gail, Bowden, Scott, Bayliss, Julianne, Luciani, Fabio, Yuen, Lilly, Fairley, Christopher K., Locarnini, Stephen, Lewin, Sharon R., and Sasadeusz, Joe

Published
2016
Full Text
View/download PDF

35. Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.

Author

Pozniak, Anton, Arribas, Jose R., Gathe, Joseph, Gupta, Samir K., Post, Frank A., Bloch, Mark, Avihingsanon, Anchalee, Crofoot, Gordon, Benson, Paul, Lichtenstein, Kenneth, Ramgopal, Moti, Chetchotisakd, Ploenchan, Custodio, Joseph M., Abram, Michael E., Xuelian Wei, Cheng, Andrew, McCallister, Scott, SenGupta, Devi, and Fordyce, Marshall W.

Published
2016
Full Text
View/download PDF

37. HIV and Noncommunicable Diseases.

Author

Ananworanich, Jintanat and Avihingsanon, Anchalee

Abstract

Asia is seeing a rise in noncommunicable diseases in their general population and among people living with HIV. Many Asians have low body weight, which can lead to higher plasma concentrations of antiretrovirals and, as a result, their toxicities. Examples are metabolic complications from protease inhibitors, chronic kidney disease from tenofovir, and hepatotoxicity from nevirapine. Asia has not only the highest burden of hepatitis B viral infection than any other continent but also a predominance of genotypes B and C, the latter associated with higher risk for hepatocellular carcinoma. HIV-associated neurocognitive disorders are equally common among Asians as other populations. Diastolic dysfunction and asymptomatic myocardial ischemia are not infrequent. Non-Hodgkin lymphoma is the most common AIDS-related cancer, whereas Kaposi sarcoma is relatively infrequent. Emerging data show high prevalence of human papillomavirus-associated anal dysplasia in men who have sex with men. Resource-limited countries in Asia suffer from lack of resources for national screening programs of noncommunicable diseases, which, in turn, limits the epidemiologic data that exist to guide the use of national health resources. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

40. Gemini: A Noninferiority Study of Saquinavir/Ritonavir Versus Lopinavir/Ritonavir as Initial HIV-1 Therapy in Adults.

Author

Walmsley, Sharon, Avihingsanon, Anchalee, Slim, Jihad, Ward, Douglas J., Ruxrungtham, Kiat, Brunetta, Jason, Bredeek, U. Fritz, Jayaweera, Dushyantha, Guittari, Carol Jean, Larson, Peter, Schutz, Malte, and Raffi, Françoiv

Subjects
*HIV, *HIV infections, *HIV-positive persons, *CD4 antigen, *TRIGLYCERIDES
Abstract

The article presents a study which compares the efficacy and safety of different agents to guide selection of optimal treatment regimens for therapy-naive to patients infected with HIV-1. Result shows that there were no significant differences in CD4 counts except for triglyceride levels, which were higher in the lopinavir/ritonavir (LPV/r) at week 48. It was concluded that saquinavir/ritonavir (SQV/r) treatment offered a better triglyceride profile to HIV-1-infected patients than LPV/r.

Published
2009
Full Text
View/download PDF

43. Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance.

Author

Preiss, Scott, Littlejohn, Margaret, Angus, Peter, Thompson, Alex, Desmond, Paul, Lewin, Sharon R., Sasadeusz, Joe, Matthews, Gail, Dore, Gregory J., Shaw, Tim, Sozzi, Vitini, Yuen, Lilly, Lau, George, Ayres, Anna, Thio, Chloe, Avihingsanon, Anchalee, Ruxrungtham, Kiat, Locarnini, Stephen, and Revill, Peter A.

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results